. 2016 Apr 29;7(22):33016–33024. doi: 10.18632/oncotarget.9108

Table 1. Delineation of 3 CML patient groups based on the percentage of CD26⁺ SCs.

Group	Patient numbers	% CD26⁺ cells of CD45⁺ 34⁺ 38⁻SCs	Proportion of SC populations
1	13/31 (42%)	75–100	dominant CD26⁺
2	11/31 (36%)	25–75	similar ratio of CD26⁺ and CD26⁻
3	7/31 (22%)	0–25	dominant CD26⁻

n – number of patients, Pt. no. – patient number.

Table 1. Delineation of 3 CML patient groups based on the percentage of CD26+ SCs.